APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Kidney International · 2025-11 · 108 (5) · 763-779
DOI: 10.1016/j.kint.2025.05.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2025-11. Verfasst von Akinlolu O Ojo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, Kansas, USA; Department of Public Health, University of Kansas…. Hauptthemen laut MEDLINE: Apolipoprotein L1, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
In people of African ancestry, apolipoprotein L1 gene (APOL1) variants have been identified as causing increased risk of progressive chronic kidney disease (CKD). In April of 2024, Kidney Disease: Improving Global Outcomes (KDIGO) convened a Controversies Conference on APOL1 Kidney Disease in Accra, Ghana. The goals of the conference were to review and discuss current evidence and controversies on APOL1 kidney disease, including naming, epidemiology, pathophysiology, APOL1 testing, treatment, and future research needs. Participants considered various terminologies for diseases related to APOL1 risk variants (such as APOL1-mediated or -induced kidney disease) and had highest support for using APOL1 kidney disease to describe kidney pathologies associated with the APOL1 G1 and G2 risk variants. Clinically, the term APOL1 kidney disease can be used on its own or as an overall category of kidney disease, with further specification added as needed (for example, APOL1 kidney disease, focal segmental glomerulosclerosis). Given that there are currently no established treatments for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable, there is insufficient evidence to guide recommendations for APOL1 population screening or routine testing. However, genotyping can be an important clinical consideration for individuals to inform risk stratification, frequency of follow-up, living kidney donation, as well as clinical trial eligibility. Key areas of need and strategies for future research were delineated and are reported here.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, Kansas, USA; Department of Public Health, University of Kansas School of Medicine, Kansas City, Kansas, USA. Electronic address: aoj…
- Department of Medicine and Therapeutics, School of Medicine, College of Health Sciences, University of Ghana, Accra, Ghana.
- Department of Renal Medicine, King's College London, London, UK.
- Department of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
- Division of Nephrology, Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston University, Boston, Massachusetts, USA.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Ojo, A. O., Adu, D., Bramham, K., Freedman, B. I., Gbadegesin, R. A., Ilori, T. O., Jefferson, N., Olabisi, O. A., Susztak, K., Young, B. A., Cheung, M., King, J. M., Grams, M. E., Jadoul, M., Ulasi, I. I., & Conference Participants (2025). APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 108(5), 763-779. https://doi.org/10.1016/j.kint.2025.05.017
Vancouver
Ojo AO, Adu D, Bramham K, Freedman BI, Gbadegesin RA, Ilori TO, et al. APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International. 2025;108(5):763-779. doi:10.1016/j.kint.2025.05.017
BibTeX
@article{Ojo2025,
author = {Ojo, Akinlolu O and Adu, Dwomoa and Bramham, Kate and Freedman, Barry I and Gbadegesin, Rasheed A and Ilori, Titilayo O and Jefferson, Nichole and Olabisi, Opeyemi A and Susztak, Katalin and Young, Bessie A and Cheung, Michael and King, Jennifer M and Grams, Morgan E and Jadoul, Michel and Ulasi, Ifeoma I and Conference Participants, Conference Participants},
title = {APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference},
journal = {Kidney International},
year = {2025},
volume = {108},
number = {5},
pages = {763--779},
doi = {10.1016/j.kint.2025.05.017}
}
EUVIMED